Atrial fibrillation affects approximately 37.6 million people worldwide. Its prevalence is predicted to double over the next 35 years. Wearable devices and technologies with diagnostic algorithms enable greater detection of this disease in the general public. Atrial fibrillation increases the risk of stroke, thromboembolism, heart failure, and death. It is associated with a decrease in the quality of life. Patients with this disease often have comorbidities. Accumulation of risk factors, including lifestyle factors, leads to worse health outcomes. With increasing age, the treatment of such patients becomes more difficult.